Fabbro D - Search Results

1

SRC family kinases: potential targets for the treatment of human cancer and leukemia.

Warmuth M, Damoiseaux R, Liu Y, Fabbro D, Gray N. Warmuth M, et al. Among authors: fabbro d. Curr Pharm Des. 2003;9(25):2043-59. doi: 10.2174/1381612033454126. Curr Pharm Des. 2003. PMID: 14529415 Review.

2

Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.

Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, Fabbro D, Hallek M, Van Etten RA, Li S. Hu Y, et al. Among authors: fabbro d. Nat Genet. 2004 May;36(5):453-61. doi: 10.1038/ng1343. Epub 2004 Apr 18. Nat Genet. 2004. PMID: 15098032 Free article.

3

Allosteric inhibitors of Bcr-abl-dependent cell proliferation.

Adrián FJ, Ding Q, Sim T, Velentza A, Sloan C, Liu Y, Zhang G, Hur W, Ding S, Manley P, Mestan J, Fabbro D, Gray NS. Adrián FJ, et al. Among authors: fabbro d. Nat Chem Biol. 2006 Feb;2(2):95-102. doi: 10.1038/nchembio760. Epub 2006 Jan 15. Nat Chem Biol. 2006. PMID: 16415863

4

Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases.

Warmuth M, Simon N, Mitina O, Mathes R, Fabbro D, Manley PW, Buchdunger E, Forster K, Moarefi I, Hallek M. Warmuth M, et al. Among authors: fabbro d. Blood. 2003 Jan 15;101(2):664-72. doi: 10.1182/blood-2002-01-0288. Epub 2002 Sep 5. Blood. 2003. PMID: 12393636 Free article.

5

Synthesis and target identification of hymenialdisine analogs.

Wan Y, Hur W, Cho CY, Liu Y, Adrian FJ, Lozach O, Bach S, Mayer T, Fabbro D, Meijer L, Gray NS. Wan Y, et al. Among authors: fabbro d. Chem Biol. 2004 Feb;11(2):247-59. doi: 10.1016/j.chembiol.2004.01.015. Chem Biol. 2004. PMID: 15123286

6

Chemical and biological profile of dual Cdk1 and Cdk2 inhibitors.

Ruetz S, Fabbro D, Zimmermann J, Meyer T, Gray N. Ruetz S, et al. Among authors: fabbro d. Curr Med Chem Anticancer Agents. 2003 Jan;3(1):1-14. doi: 10.2174/1568011033353605. Curr Med Chem Anticancer Agents. 2003. PMID: 12678910 Review.

7

Discovery of allosteric BCR-ABL inhibitors from phenotypic screen to clinical candidate.

Gray NS, Fabbro D. Gray NS, et al. Among authors: fabbro d. Methods Enzymol. 2014;548:173-88. doi: 10.1016/B978-0-12-397918-6.00007-0. Methods Enzymol. 2014. PMID: 25399646 Review.

8

Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site.

Fabbro D, Manley PW, Jahnke W, Liebetanz J, Szyttenholm A, Fendrich G, Strauss A, Zhang J, Gray NS, Adrian F, Warmuth M, Pelle X, Grotzfeld R, Berst F, Marzinzik A, Cowan-Jacob SW, Furet P, Mestan J. Fabbro D, et al. Biochim Biophys Acta. 2010 Mar;1804(3):454-62. doi: 10.1016/j.bbapap.2009.12.009. Biochim Biophys Acta. 2010. PMID: 20152788

9

The Dawn of Allosteric BCR-ABL1 Drugs: From a Phenotypic Screening Hit to an Approved Drug.

Teng M, Luskin MR, Cowan-Jacob SW, Ding Q, Fabbro D, Gray NS. Teng M, et al. Among authors: fabbro d. J Med Chem. 2022 Jun 9;65(11):7581-7594. doi: 10.1021/acs.jmedchem.2c00373. Epub 2022 May 24. J Med Chem. 2022. PMID: 35609336 Review.

10

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.

Schoepfer J, Jahnke W, Berellini G, Buonamici S, Cotesta S, Cowan-Jacob SW, Dodd S, Drueckes P, Fabbro D, Gabriel T, Groell JM, Grotzfeld RM, Hassan AQ, Henry C, Iyer V, Jones D, Lombardo F, Loo A, Manley PW, Pellé X, Rummel G, Salem B, Warmuth M, Wylie AA, Zoller T, Marzinzik AL, Furet P. Schoepfer J, et al. Among authors: fabbro d. J Med Chem. 2018 Sep 27;61(18):8120-8135. doi: 10.1021/acs.jmedchem.8b01040. Epub 2018 Sep 7. J Med Chem. 2018. PMID: 30137981

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

402 results

Search Page

Filters